NCATS Skeptics

The US National Institutes of Health has fielded a lot of skepticism regarding the National Center for Advancing Translational Sciences. Many in the research and funding communities say drug discovery is best left to pharmaceutical and biotech companies and NIH should concentrate on its basic research mandate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

An NCATS License

The Mouse Version

Make It a Double

A Model Organ

Making the Most

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."